Please assess the completion status of the following clinical trial:

Trial Title: A Trial Comparing the Efficacy, Patient-reported Outcomes and Safety of Insulin Degludec 200 U/mL vs Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Requiring High-dose Insulin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Type 2 diabetes~* Current treatment with once daily insulin glargine in vials with a daily dose equal to or above 65 U and equal to or below 100 U~* Current treatment with a stable dose of metformin plus/minus one additional oral antidiabetic drug (OAD) for at least 12 weeks~* Glycosylated haemoglobin (HbA1c) equal to or above 7.5%~Exclusion Criteria:~* Current treatment with insulin other than insulin glargine in vials~* Treatment with thiazolidinediones or glucagon-like peptide-1 (GLP-1) receptor agonists within 12 weeks~* Stroke; heart failure; myocardial infarction; unstable angina pectoris; coronary arterial bypass graft or angioplasty~* Suffer from cancer (except basal cell skin cancer and squamous-cell cancer)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- IDeg followed by IGlar (Type: EXPERIMENTAL): None
- IGlar followed by IDeg (Type: EXPERIMENTAL): None

Based on this trial design, predict the completion outcome and termination type (if applicable).